Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) shares were down 3.9% on Monday . The stock traded as low as $18.68 and last traded at $18.88. Approximately 3,197 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 287,131 shares. The stock had previously closed at $19.64.
Crinetics Pharmaceuticals Price Performance
The firm has a 50-day moving average price of $20.33 and a two-hundred day moving average price of $20.11.
Get
Crinetics Pharmaceuticals alerts:
Insider Activity
In other news, Director Matthew K. Fust sold 5,700 shares of the stock in a transaction that occurred on Wednesday, July 13th. The stock was sold at an average price of $20.96, for a total value of $119,472.00. Following the completion of the sale, the director now directly owns 12,536 shares of the company's stock, valued at $262,754.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Stephen F. Betz sold 4,168 shares of the company's stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $21.01, for a total value of $87,569.68. Following the completion of the transaction, the insider now directly owns 100,598 shares in the company, valued at $2,113,563.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Matthew K. Fust sold 5,700 shares of the company's stock in a transaction on Wednesday, July 13th. The shares were sold at an average price of $20.96, for a total value of $119,472.00. Following the completion of the transaction, the director now owns 12,536 shares of the company's stock, valued at $262,754.56. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,062 shares of company stock valued at $252,770. 5.90% of the stock is owned by company insiders.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of CRNX. Cubist Systematic Strategies LLC raised its stake in shares of Crinetics Pharmaceuticals by 70.4% in the second quarter. Cubist Systematic Strategies LLC now owns 8,478 shares of the company's stock valued at $158,000 after purchasing an additional 3,503 shares in the last quarter. Dupont Capital Management Corp raised its stake in shares of Crinetics Pharmaceuticals by 36.3% in the second quarter. Dupont Capital Management Corp now owns 8,629 shares of the company's stock valued at $161,000 after purchasing an additional 2,297 shares in the last quarter. Group One Trading L.P. raised its stake in shares of Crinetics Pharmaceuticals by 31.6% in the first quarter. Group One Trading L.P. now owns 7,318 shares of the company's stock valued at $161,000 after purchasing an additional 1,759 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Crinetics Pharmaceuticals by 17.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,493 shares of the company's stock worth $164,000 after acquiring an additional 1,110 shares in the last quarter. Finally, Arizona State Retirement System acquired a new position in Crinetics Pharmaceuticals during the second quarter worth $188,000. 94.42% of the stock is currently owned by institutional investors and hedge funds.
Crinetics Pharmaceuticals Company Profile
(Get Rating)
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
Featured Stories
- Get a free copy of the StockNews.com research report on Crinetics Pharmaceuticals (CRNX)
- Don't Give Up on These Q3 Losers
- The Anatomy of a Great Pension Plan
- 3 Safe Earnings Plays for a Risk-Off Market
- Tyson Foods Takes a Lickin' and Keeps on Tickin' Lower
- Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
